SCHEMBL5548259

SCHEMBL5548259

O=[C]OC/C=C/c1cccc(OC(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
CHRM2 P08172 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
CHEK1 O14757 1/20 0.38
DAO P14920 1/20 0.37
EPOR P19235 1/20 0.36
KIF11 P52732 1/20 0.36
FFAR1 O14842 1/20 0.36
TRPV1 Q8NER1 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALOX5 P09917 1/20 0.34
ALOX5AP P20292 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
NFE2L2 Q16236 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548260 1.00 PIM1 (0.42) PIM1PIM2CHRM2CHRM1CHRM3
SCHEMBL5544041 0.85 GRIK1 (0.33)
SCHEMBL2091108 0.83 PIM1 (0.44) PIM1PIM2CHRM2CHRM1CHRM3
SCHEMBL5543896 0.83 FBP1 (0.49) MAOAMAOBNFE2L2FBP1
SCHEMBL2091112 0.83 PIM1 (0.44) PIM1PIM2CHRM2CHRM1CHRM3
SCHEMBL5543899 0.83 FBP1 (0.49) MAOAMAOBNFE2L2FBP1
SCHEMBL5536477 0.82 GRIK1 (0.46) PIM1PIM2DAOMAOB
SCHEMBL5536474 0.82 GRIK1 (0.46) PIM1PIM2DAOMAOB
SCHEMBL2093427 0.81 PIM1 (0.42) PIM1PIM2CHRM2CHRM1CHRM3
SCHEMBL2093429 0.81 PIM1 (0.42) PIM1PIM2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PIM1 3129/4885PIM2 2557/4885CHRM2 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.